[Efficacy and safety of divozilimab during 24-week treatment of multiple sclerosis patients in randomized double-blind placebo-controlled clinical trial BCD-132-2].
A N BoykoValentina M AlifirovaI G LukashevichZoya A GoncharovaI V GreshnovaL G ZaslavskyS V KotovN A MalkovaG N MishinYe V ParshinaI Ye PoverennovaL N PrakhovaStella SivertsevaI V SmaginaN A TotolyanYu V TrinitatskyT N TrushnikovaF A KhabirovS G ShchurA V ArtemevaD D BolsunArina V Zinkina-OrikhanYulia N LinkovaPublished in: Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova (2023)
Thus, the assessment of 24 weeks treatment demonstrated that DIV is a highly effective, safe and convenient option for the treatment of RRMS patients, both naive and previously treated with disease modifying therapy. A dose of 500 mg is recommended for further efficacy and safety evaluation during phase 3 CT.
Keyphrases
- double blind
- placebo controlled
- clinical trial
- end stage renal disease
- multiple sclerosis
- newly diagnosed
- ejection fraction
- chronic kidney disease
- phase ii
- open label
- prognostic factors
- phase iii
- randomized controlled trial
- study protocol
- peritoneal dialysis
- radiation therapy
- stem cells
- squamous cell carcinoma
- positron emission tomography
- combination therapy
- gestational age